TABLE 3.
Pathology in the Fovea, N (%) | Month 6 (N = 15)b | Month 12 (N = 15) | Month 24 (N = 15) | Month 36 (N = 11) | Month 48 (N = 10) | Month 60 (N = 5) |
---|---|---|---|---|---|---|
SR hemorrhage | 3 (20.0) | 0 | 0 | 0 | 0 | 0 |
Atrophy | 0 | 1 (6.7) | 2 (13.3) | 2 (18.2) | 2 (20.0) | 1 (20.0) |
RPE changes | 3 (20.0) | 1 (6.7) | 0 | 0 | 0 | 0 |
SRHRM | 5 (33.3) | 8 (53.3) | 8 (53.3) | 6 (54.5) | 6 (60.0) | 2 (40.0) |
SR fibrosis,a N/n (%) | 5/5 (100) | 6/8 (75.0) | 7/8 (87.5) | 6/6 (100) | 6/6 (100) | 2/2 (100) |
Sub-RPE HRM | 0 | 1 (6.7) | 1 (6.7) | 0 | 0 | 0 |
CNV = choroidal neovascularization; HRM = hyperreflective material; RPE = retinal pigment epithelium; SR = subretinal; SRHRM = subretinal hyperreflective material.
Subretinal fibrosis was defined as subretinal hyperreflective material with well-demarcated, sharp borders and loss or disruption of overlying ellipsoid zone and external limiting membrane on spectral-domain optical coherence tomography.
Images for 1 patient were unavailable for month 6 visit.